Anti-Bundibugyo Ebolavirus, GP (Clone BDBV-357) -Purified No Carrier Protein

Specificity: BDBV-357 activity is directed against Bundibugyo ebolavirus (BDBV) glycoprotein (GP) . Antigen Distribution: Ebola virus glycoprotein is a surface protein expressed on the virus envelope. Background: Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90%1. Three Ebola species are responsible for lethal outbreaks: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV) . The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell, endosomal entry, and membrane fusion1. GP is composed of two subunits, GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop, transmembrane domain, and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus1,2,3. BDBV-357 is a GP mAb isolated from B cells of a survivor of the 2007 Uganda BDBV outbreak3. Peripheral blood mononuclear cells from the survivor were transformed with Epstein-Barr virus, CpG, and additional supplements. Subsequently, cell supernatants were screened by ELISA for binding to GPs from BDBV, EBOV, or MARV filoviruses. Positive cells were fused with HMMA2.5 myeloma cells by electrofusion and cloned by single-cell fluorescence-activated cell sorting. BDBV-357 binds with strong affinity to both native BDBV GP and a recombinant GP secreted to the extracellular space during infection (sGP) 3. sGP and GP share 295 residues at the N-terminus. Additionally, BDBV-357 binds to EBOV GP with intermediate affinity. BDBV-357 does not neutralize BDBV.